Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 7544486
Nell peptide expression systems and bone formation activity of nell peptide
granted -
US 7541429
Comparative ligand mapping from MHC positive cells
granted -
US 7541346
Pancratistatin cyclic phosphate prodrugs and phenpanstatin cyclic phosphate prodrugs
granted -
US 7537759
Modulating angiogenesis
granted -
US 7538129
Diazonamide A analog
granted -
US 7534440
Fusion molecules and methods for treatment of immune diseases
granted -
US 7534859
Protein kinase C epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
granted -
US 7534764
Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
granted -
US 7534613
Methods of treating parkinson's disease using viral vectors
granted -
US 7534418
Imaging agents
granted -
US 7531162
Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
granted -
US 7531500
Preventing airway mucus production by administration of EGF-R antagonists
granted -
US 7531514
Orally administered peptides synergize statin activity
granted -
US 7531355
Methods and compositions for smooth muscle reconstruction
granted -
US 7527934
Labeled substrate conjugates for identifying enzyme inhibitors
granted -
US 7528133
Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
granted -
US 7527786
Methods for inhibiting the growth of cancer cells expressing PSCA
granted -
US 7524944
Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-Ξ±
granted -
US 7524490
Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site
granted -
US 7521414
Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140
granted -
US 7521175
Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
granted -
US 7521535
Anti-microbial defensin-related peptides and methods of use
granted -
US 7517858
Prodrugs of pharmaceuticals with improved bioavailability
granted -
US 7517971
Muteins of human telomerase reverse transcriptase lacking telomerase catalytic activity
granted -
US 7517895
Synthetic diazonamides
granted -
US 7514095
Fabrication of drug loaded biodegradable polymer fibers
granted -
US 7510710
Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
granted -
US 7512436
Method of evaluating metabolism of the eye
granted -
US 7511124
Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
granted -
US 7507716
Method for treating pain with prolactin antagonists
granted -
US 7507407
Immunoliposomes that optimize internationalization into target cells
granted -
US 7507556
Nucleic acids encoding rat hyaluronan receptor for endocytosis
granted -
US 7507422
Urinary tract tissue graft compositions and methods for producing same
granted -
US 7504233
Methods for determining the metabolism of sugars and fats in an individual
granted -
US 7504231
Method of alleviating chronic pain via peripheral inhibition of neurotransmitter synthesis
granted -
US 7504246
Hyaluronan synthase gene and uses thereof
granted -
US 7504435
Method for stimulating weight loss and/or for lowering triglycerides in patients
granted -
US 7498170
Bone precursor cells: compositions and methods
granted -
US 7495090
Nucleic acids encoding chimeric CD154 polypeptides
granted -
US 7494653
Method and compositions for immunization with the Pseudomonas V antigen
granted -
US 7494775
Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
granted -
US 7494644
Methods and compositions for correction of cardiac conduction disturbances
granted -
US 7494666
Cationic lipid compositions targeting angiogenic endothelial cells
granted -
US 7488480
Use of passive myostatin immunization in egg laying vertebrates
granted -
US 7488804
Modified fusion molecules for treatment of allergic disease
granted -
US 7485660
Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
granted -
US 7485311
Methods and compositions for preventing and treating male erectile dysfunction
granted -
US 7485296
PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory